D. Robinson

发表

A multicenter, phase II study of infliximab plus gemcitabine in pancreatic cancer cachexia.

P. Malfertheiner, H. Friess, E. Van Cutsem, 2008, The journal of supportive oncology.

Clinical epidemiology and treatment patterns of patients with multicentric Castleman disease: results from two US treatment centres

T. Habermann, H. van de Velde, A. Dispenzieri, 2014, British journal of haematology.

Cardiovascular disease and risk factors in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.

M. Bala, Chenglong Han, D. Robinson, 2006, The Journal of rheumatology.

The burden of autoimmune disease: a comparison of prevalence ratios in patients with psoriatic arthritis and psoriasis.

A. Kimball, M. Bala, Maryanne Makredes, 2009, Journal of the American Academy of Dermatology.

Pain questionnaire performance in advanced prostate cancer: comparative results from two international clinical trials

D. Revicki, F. Dawkins, M. Qi, 2013, Quality of Life Research.

Autoimmune disease concomitance among inflammatory bowel disease patients in the United States, 2001‐2002

M. Bala, D. Robinson, R. Cohen, 2008, Inflammatory bowel diseases.

Systemic sclerosis prevalence and comorbidities in the US, 2001-2002.

M. Bala, P. Nietert, D. Robinson, 2008, Current medical research and opinion.

D. Esseltine, P. Richardson, J. S. San Miguel, 2012, European journal of haematology.

Health and Quality of Life Outcomes

D. Cella, D. Revicki, D. Robinson, 2003 .

Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial.

D. Cella, D. Revicki, D. Robinson, 2009, Current medical research and opinion.

The influence of baseline characteristics and disease stage on health‐related quality of life in multiple myeloma: findings from six randomized controlled trials

D. Esseltine, H. van de Velde, A. Regnault, 2016, British journal of haematology.

Are inflammatory cytokines the common link between cancer-associated cachexia and depression?

J. Rossi, D. Cella, M. Trikha, 2005, The journal of supportive oncology.

Health and Quality of Life Outcomes

P. Shekelle, R. Hays, D. Cella, 2003 .

Co-occurrence and comorbidities in patients with immune-mediated inflammatory disorders: an exploration using US healthcare claims data, 2001–2002

A. Kimball, M. Bala, J. Wong, 2006, Current medical research and opinion.

D. Cella, D. Revicki, J. Cormier, 2012, Melanoma research.

Anti-TNF-α Antibody and Cancer Cachexia

D. Robinson, Mark S. Anderson, M. Witte, 2006 .

A Comparison of the Renal Cell Carcinoma-Symptom Index (RCC-SI) and the Functional Assessment of Cancer Therapy-Kidney Symptom Index (FKSI).

J. V. Von Roenn, D. Cella, D. Rao, 2009, Journal of pain and symptom management.

Randomized phase II study of bortezomib, thalidomide, and dexamethasone with or without cyclophosphamide as induction therapy in previously untreated multiple myeloma.

R. Greil, R. Hájek, B. Paiva, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Clinical characteristics and healthcare utilization of patients with multicentric Castleman disease

T. Habermann, A. Dispenzieri, M. Reynolds, 2015, British journal of haematology.

The prognostic significance of patient-reported outcomes in pancreatic cancer cachexia.

David Cella, D. Cella, M. DeWitte, 2008, The journal of supportive oncology.

Content development for the Functional Assessment of Cancer Therapy-Multiple Myeloma (FACT-MM): use of qualitative and quantitative methods for scale construction.

R. Fonseca, D. Cella, D. Robinson, 2012, Journal of pain and symptom management.

Bortezomib‐based therapy for relapsed/refractory multiple myeloma in real‐world medical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, European journal of haematology.

Bortezomib, thalidomide and dexamethasone, with or without cyclophosphamide, for patients with previously untreated multiple myeloma: 5‐year follow‐up

R. Greil, R. Hájek, B. Paiva, 2015, British journal of haematology.

Systemic sclerosis prevalence and comorbidities in the US, 2001–2002

M. Bala, P. Nietert, D. Robinson, 2008 .

Symptom burden among patients with Renal Cell Carcinoma (RCC): content for a symptom index

D. Cella, D. Revicki, D. Robinson, 2007, Health and quality of life outcomes.

Health perceptions and clinical characteristics of relapsing-remitting multiple sclerosis patients: baseline data from an international clinical trial

D. Cella, D. Revicki, D. Robinson, 2009 .

Impact of systemic lupus erythematosus on health, family, and work: The patient perspective

D. Cella, D. Revicki, M. Weisman, 2010, Arthritis care & research.

Bortezomib retreatment for relapsed and refractory multiple myeloma in real‐world clinical practice

M. Dimopoulos, A. Belch, E. Katodritou, 2018, Health science reports.

Sustained Health-Related Quality of Life (HRQoL) Improvement in Newly Diagnosed Multiple Myeloma Patients Treated with Bortezomib/Melphalan/Prednisone Versus Melphalan/Prednisone: Results From the VISTA Trial.

J. Miguel, P. Richardson, A. Regnault, 2009 .

A352 Impact of Complete Response on Quality of Life in Newly Diagnosed Multiple Myeloma Patients

J. Miguel, P. Richardson, A. Regnault, 2009 .

Economic burden of relapsed or refractory multiple myeloma: Results from an international trial

R. Orlowski, D. Robinson, A. Chitnis, 2017, European journal of haematology.

Cardiovascular Disease and Risk Factors among Psoriasis Patients in Two US Healthcare Databases, 2001–2002

A. Kimball, M. Bala, C. Guzzo, 2008, Dermatology.